Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research ...

The cuts aim to help Pfizer recover from the rapid decline of its Covid business and stock price over the last few years, and ...

Pfizer also beat analyst expectations for first-quarter earnings as it benefited from cost-saving efforts, although it fell short of Wall Street’s revenue estimate, as sales of its COVID-19 ...

Pfizer Q1 EPS beat at $0.92 vs. $0.67 estimate, but sales dipped 8% YoY to $13.71 billion, below $13.95 billion forecast. Paxlovid sales plunged 75%, while Vyndaqel jumped 33% and Comirnaty rose ...

Pfizer said Paxlovid sales fell $1.5 billion, or 75%, to roughly $500 million, partly due to lower COVID-19 infections in the U.S. and a drop in purchases by governments. On the plus side ...

Additionally, Comirnaty, Pfizer’s Covid-19 vaccine, brought in $565 million in sales during the quarter, significantly higher than the $354 million revenue recorded in the same quarter last year.

Experts are urging Australians to get vaccinated before winter to protect themselves and their families, amid fears cases of Covid and other illnesses could spike. Reports of Covid variant LP.8.1 ...

Analysts significantly cut their Paxlovid sales expectations in recent weeks due to a relatively small winter wave of COVID-19 in the U.S. On an adjusted basis, Pfizer earned 92 cents per share in ...

It's not the first time Pfizer and BioNTech have been accused of patent infringement with Comirnaty, as another mRNA COVID-19 vaccine developer – CureVac – filed a suit in Germany last month ...

Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research operations, highlighting its operational efficiency even as it reported lower ...